Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D.
09:00am, Monday, 22'nd Feb 2021
REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t
REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t
Can The Gains Continue For Adverum Biosciences After An 18% Move In 5 Days?
06:30am, Friday, 22'nd Jan 2021
Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclosed in re
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
12:47pm, Monday, 11'th Jan 2021
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Implied Volatility Surging for Adverum Biotechnologies (ADVM) Stock Options
09:47am, Friday, 08'th Jan 2021
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
11:57am, Thursday, 07'th Jan 2021
-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites with to
Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference
11:00am, Monday, 23'rd Nov 2020
REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t
-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after a single IVT injection of ADVM-022 -- -- R obust preliminary aqueous a nti-VEGF protein expression observed at 18 months i
Adverum Biotechnologies (NASDAQ:ADVM) Rating Increased to Hold at Zacks Investment Research
04:46am, Wednesday, 14'th Oct 2020
Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a sell rating to a hold rating in a research report report published on Tuesday, Zacks.com reports. According to
Assessing Adverum (NASDAQ:ADVM)
05:45pm, Tuesday, 29'th Sep 2020
Today, we take an in-depth look at Adverum Biotechnologies which has dropped by more than half from highs earlier this year.
AQR Capital Management LLC Cuts Stock Holdings in Adverum Biotechnologies Inc (NASDAQ:ADVM)
08:20am, Sunday, 27'th Sep 2020
AQR Capital Management LLC reduced its position in shares of Adverum Biotechnologies Inc (NASDAQ:ADVM) by 49.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Secu
26,924 Shares in Adverum Biotechnologies Inc (NASDAQ:ADVM) Acquired by Virtu Financial LLC
08:30am, Sunday, 23'rd Aug 2020
Virtu Financial LLC bought a new position in shares of Adverum Biotechnologies Inc (NASDAQ:ADVM) during the second quarter, according to the company in its most recent disclosure with the Securities a
Opinion | The White House Prepared for a Pandemic
11:16pm, Tuesday, 18'th Aug 2020
A September 2019 report laid the groundwork for Operation Warp Speed.
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock
01:00pm, Tuesday, 18'th Aug 2020
REDWOOD CITY, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t
Adverum (ADVM) Surges: Stock Moves 6.2% Higher
12:51pm, Monday, 17'th Aug 2020
Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
